Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide.
Abramson
N
N
Stokes
P K
PK
Luke
Mathew
M
Marks
Alan R
AR
Harris
Jeffrey M
JM
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D018394:CA-125 Antigen / Q000032:analysis; D002291:Carcinoma, Papillary / Q000188:drug therapy*; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D010865:Pilot Projects; D013792:Thalidomide / Q000008:administration & dosage / Q000494:pharmacology*; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D018394:CA-125 Antigen; D013792:Thalidomide